Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0072 • ACR Convergence 2020
Characterizing Heterogeneity of Synovial Macrophages in Rheumatoid Arthritis Patients
Shang-Yang Chen¹, Yidan Wang², Anna Montgomery², Salina Dominguez², Carla Cuda², Gaurav Gadhvi¹, Harris Perlman² and Deborah Winter³, ¹Northwestern University, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern University Division of Rheumatology, Chicago, IL
Background/Purpose: Macrophages in the synovial lining of the joint are critical players in the pathogenesis of rheumatoid arthritis (RA). While they are potent producers of…
Abstract Number: 0142 • ACR Convergence 2020
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs: Results from the FINCH 2 Study
Zobair Younossi¹, Maria Stepanova², Lynn Gerber¹, Susan Lee³, I-Heng Lee⁴, Thijs Hendrikx⁵, Annelies Boonen⁶, Rieke Alten⁷, Bernard Combe⁸ and David Walker⁹, ¹Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, ²Center for Outcomes Research in Liver Disease, Washington, DC, ³Gilead Sciences, Inc., Foster City, CA, ⁴Gilead Sciences, Foster City, CA, ⁵Galapagos BV, Leiden, Netherlands, ⁶Maastricht University Medical Center, Maastricht, Netherlands, ⁷Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany, ⁸University of Montpellier, Montpellier, France, ⁹Northumbria Healthcare Trust, North Shields, United Kingdom
Background/Purpose: Filgotinib (FIL) is a potent oral selective janus kinase 1 inhibitor which is currently being investigated as an agent to treat rheumatoid arthritis (RA).…
Abstract Number: 0180 • ACR Convergence 2020
Clinicopathological Characteristics of Lymphoproliferative Disorders in 232 Patients with Rheumatoid Arthritis in Japan
Hideto Takada¹, Yuko Kaneko², Kazuhisa Nakano³, Masao Tanaka⁴, Takao Fujii⁵, Kazuyoshi Saito⁶, Naoki Sugimoto¹, Shoh Sasaki⁷, Shuntaro Saito², Rintaro Saito⁸, Nobuo Kuramoto⁵, Yasuo Suzuki⁷ and Masayoshi Harigai¹, ¹Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ³The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu-shi, Fukuoka, Japan, ⁴Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan, ⁵Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Wakayama, Japan, ⁶Tobata General Hospital, Kitakyushu, Fukuoka, Japan, ⁷Division of Rheumatology, Tokai University Hachioji Hospital, Hachioji, Tokyo, Japan, ⁸Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan
Background/Purpose: Lymphoproliferative disorders (LPDs) in patients with rheumatoid arthritis (RA) are one of potentially life-threatening complications. However, the diagnosis of LPDs is complicated by the…
Abstract Number: 0197 • ACR Convergence 2020
The Clinical and Laboratory Features of Seronegative Rheumatoid Arthritis with and Without Malignancy
Misako Higashida-Konishi¹, Keisuke Izumi², Satoshi Hama², Hiroshi Takei², Yutaka Okano³ and Hisaji Ohshima², ¹Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Meguro-ku, Tokyo, Japan, ²Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Tokyo, Japan, ³Department of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, Kawasaki, Japan
Background/Purpose: Patients with elderly onset rheumatoid arthritis(RA) have been reported to be less positive for RF(rheumatoid factor) and ACPA(anti-cyclic citrullinated peptide antibody), and have a…
Abstract Number: 0213 • ACR Convergence 2020
Sustainability of Response to Upadacitinib as Monotherapy or in Combination Among Patients with Rheumatoid Arthritis and Prior Inadequate Response to Conventional Synthetic DMARDs
Arthur Kavanaugh¹, Maya Buch², Bernard Combe³, Louis Bessette⁴, In-Ho Song⁵, Yanna Song⁶, Jessica Suboticki⁵ and Peter Nash⁷, ¹Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ²Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, ³University of Montpellier, Montpellier, France, ⁴Laval University, Quebec, Canada, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., North Chicago,, IL, ⁷School of Medicine Griffith University, Brisbane, Queensland, Australia
Background/Purpose: To assess long-term sustainability of responses to upadacitinib (UPA), a JAK inhibitor, with or without background csDMARD(s) in patients (pts) with rheumatoid arthritis (RA).Methods:…
Abstract Number: 0230 • ACR Convergence 2020
Effect of Dose Escalation of Subcutaneous Tocilizumab on Disease Activity in Patients with Rheumatoid Arthritis in a Randomized Controlled Trial
Nora G. Singer¹, Shalini V. Mohan², Jeffrey Yourish³, Jian Han², Michael Edwardes⁴ and Margaret Michalska³, ¹Case Western Reserve University and MetroHealth System, Cleveland, ²Genentech, South San Francisco, CA, ³Genentech, Inc., South San Francisco, ⁴Everest Clinical Research, Ontario, Canada
Background/Purpose: In patients with rheumatoid arthritis (RA), subcutaneous tocilizumab (TCZ-SC) is administered every 2 weeks (q2w) or every week (qw), based on the patient’s weight…
Abstract Number: 0444 • ACR Convergence 2020
Chronological Order of Decrease of Synovitis, Osteitis and Tenosynovitis in Early Arthritis Patients Receiving First DMARD-treatment
Xanthe Matthijssen¹, Ellis Niemantsverdriet¹, Saskia le Cessie¹ and Annette van der Helm - van Mil², ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Advanced imaging modalities have shown that not only joints but also bones and tendon sheaths can be inflamed at diagnosis of rheumatoid arthritis. We…
Abstract Number: 0490 • ACR Convergence 2020
Fine Specificity Anti-Citrullinated Protein Antibodies as Biomarkers for Prediction of Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease
Vanessa Kronzer¹, Weixing Huang², Paul Dellaripa³, Sicong Huang⁴, Vivi Feathers², Bing Lu⁵, Christine Iannaccone⁴, Ritu Gill⁶, Hiroto Hatabu⁷, Mizuki Nishino⁷, Cynthia Crowson⁸, John Davis¹, William Robinson⁹, Tripta Rughwani⁹, Jeremy Sokolove¹⁰, Michael Weinblatt⁴, Nancy Shadick¹¹, Tracy J. Doyle¹² and Jeffrey Sparks¹¹, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Newton, MA, ⁶Beth Israel Deaconess Medical Center, Boston, MA, ⁷Department of Radiology; Brigham and Women’s Hospital, Boston, ⁸Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ⁹Stanford University, Palo Alto, CA, ¹⁰Stanford University, Mountain View, CA, ¹¹Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹²Brigham and Women's Hospital, West Roxbury, MA
Background/Purpose: Seropositivity for anti-citrullinated protein antibodies (ACPA) has been shown to increase risk for RA-associated interstitial lung disease (RA-ILD). However, RA-related autoantibodies used in clinical…
Abstract Number: 0692 • ACR Convergence 2020
Pre-Operative Opioid Usage Increases Length of Stay for Rheumatoid Arthritis Patients Undergoing Total Hip Arthroplasty and Total Knee Arthroplasty
Kyle Morse¹, Nicole Heinz¹, Jeremy Abolade¹, Joshua Wright-Chisem¹, Linda Russell², Meng Zhang³, Serene Mirza¹, Dana Orange⁴, Mark Figgie⁵, Peter Sculco² and Susan Goodman⁵, ¹Hospital for Special Surgery, New York, ²Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ³Feinstein Institute, Northwell Health, New York, ⁴Rockefeller University, New York, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Total Hip (THA) and total knee arthroplasty (TKA) are cost-effective procedures that improve the health-related quality of life for patients with advanced symptomatic joint…
Abstract Number: 0755 • ACR Convergence 2020
Exploring the Significance of Anti-Nuclear Antibody Positivity in the Medical Management of Patients with Rheumatoid Arthritis
Sujaytha Paknikar¹, Cynthia Crowson², John Davis¹ and Uma Thanarajasingam¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: ANA testing has been a well-established screening tool for autoimmune conditions such as SLE. Current practice for classification of RA does not include ANA…
Abstract Number: 0773 • ACR Convergence 2020
The Anti-carbamylated Fibrinogen Response in Rheumatoid Arthritis Targets a Specific Epitope on the γ-chain and Is Associated with a More Active Disease
Pauline Brevet¹, Manuel Freret¹, Pascal Rottenberg², Clément Guillou³, Thierry Lequerre⁴, Pascal Cosette⁵, Olivier Boyer² and Olivier Vittecoq⁶, ¹Inserm U1234 and Rouen University , IRIB, Rouen, France ; Rouen University Hospital, Rheumatology Department, Rouen, France, Rouen, Haute-Normandie, France, ²Inserm U1234 and Rouen University , IRIB, Rouen, France ; Rouen University Hospital, Rheumatology Department, Rouen, France, Rouen, France, ³CNRS 6270, PISSARO, IRIB, Rouen, France ; Centre hospitalo-universitaire de Rouen, Immunology Laboratory, Rouen, France, Rouen, Haute-Normandie, France, ⁴Rheumatology, University Teaching Hospital, Rouen, France, ⁵CNRS 6270, PISSARO, IRIB, Rouen, France ; Centre hospitalo-universitaire de Rouen, Immunology Laboratory, Rouen, France, Rouen, France, ⁶University Hospital of Rouen, Rouen, France
Background/Purpose: Anti-carbamylated protein autoantibodies (anti-CarP Abs) of IgG and/or IgA isotype have potential diagnostic and prognostic value Carbamylated Fetal Calf Serum (FCS) is the substrate…
Abstract Number: 0790 • ACR Convergence 2020
Vitamin D Polygenetic Risk Score and the Association with RA Autoantibodies Among First-Degree Relatives of RA Subjects
Elizabeth Bemis¹, Kendra Young², Jennifer Seifert³, Marie Feser⁴, Kevin D. Deane⁵, M Kristen Demoruelle⁶, James O'Dell⁷, Michael Weisman⁸, Peter Gregersen⁹, Richard Keating¹⁰, William Robinson¹¹, Jane Buckner¹², Carl Langefeld¹³, Joel Guthridge¹⁴, Judith James¹⁵, V Michael Holers⁴ and Jill Norris¹⁶, ¹Colorado School of Public Health Anschutz Medical Campus, Aurora, CO, ²University of Colorado Denver, Aurora, CO, ³UC Denver, Littleton, CO, ⁴Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁵2 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁶University of Colorado, Denver, CO, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹5. Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY, ¹⁰Scripps Clinic/Scripps Green Hospital, La Jolla, CA, ¹¹Stanford University, Palo Alto, CA, ¹²Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ¹³Wake Forest School of Medicine, Winston Salem, NC, ¹⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, ¹⁶Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, Colorado
Background/Purpose: Rheumatoid arthritis (RA) is a complex autoimmune disease whose etiology remains largely unknown. Vitamin D has been widely studied due to its association with…
Abstract Number: 0806 • ACR Convergence 2020
Identification and Adjustment for Factors Associated with Clinical Response in Rheumatoid Arthritis Clinical Trials to Improve Comparisons of Treatment Efficacy
Anthony Cordisco¹ and Joshua Baker¹, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Numerous clinical trials have been published in rheumatoid arthritis (RA), but comparing efficacies of disease-modifying anti-rheumatic drugs (DMARDs) is complicated by a lack of…
Abstract Number: 0823 • ACR Convergence 2020
Identifying Physician-Perceived Barriers to a Pragmatic Treatment Trial in Rheumatoid Arthritis
Haiyan Qu¹, Shamly Austin² and Jasvinder Singh¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Gateway Health Plan®, Pittsburgh, PA
Background/Purpose: The aim of this qualitative research was to identify physician-perceived patient and clinic barriers to patient recruitment in a RA pragmatic trial of anti-TNF…
Abstract Number: 0966 • ACR Convergence 2020
Decoupling Inflammation and Bone Loss in Rheumatoid Arthritis via Schnurri-3
Zheni Stavre¹, JungMin Kim², Jae-Hyuck Shim² and Ellen Gravallese³, ¹University of Massachusetts Medical School-Rheumatology Division, Worcester, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that leads to local and systemic bone loss. TNF is a key mediator of bone loss,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].